# UP-818-CC Injection in Healthy Chinese Subjects

> **NCT07355621** · PHASE1 · COMPLETED · sponsor: **EnliTISA (Shanghai) Pharmaceutical Co., Ltd.** · enrollment: 73 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** UP-818-CC injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07355621
- **Lead sponsor:** EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-14
- **Primary completion:** 2023-01-12
- **Final completion:** 2023-02-20
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07355621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07355621, "UP-818-CC Injection in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07355621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*